4D Molecular Therapeutics Reports FY 2025 Financial Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy FDMT?
Source: seekingalpha
- Earnings Performance: 4D Molecular Therapeutics reported a FY 2025 GAAP EPS of -$2.42, beating expectations by $0.98, indicating potential improvement in the company's financial performance.
- Collaboration Revenue Growth: The company achieved $85 million in collaboration and license revenue for 2025, a significant increase from $0 in 2024, marking a notable advancement in its commercialization efforts and laying a foundation for future growth.
- Cash Reserves: As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $514 million, ensuring ample funding for R&D and operations, thereby enhancing its competitive position in the market.
- Reduced Net Loss: The net loss for 2025 was $140 million, down from $161 million in 2024, reflecting improvements in cost control and operational efficiency, which may attract increased investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FDMT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FDMT
Wall Street analysts forecast FDMT stock price to rise
6 Analyst Rating
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 9.330
Low
17.00
Averages
29.40
High
38.00
Current: 9.330
Low
17.00
Averages
29.40
High
38.00
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
4D Molecular Therapeutics Reports 2025 Financial Highlights
- Revenue Growth: In 2025, 4D Molecular Therapeutics reported collaboration and license revenue of $85 million, primarily driven by an upfront payment from its strategic partnership with Otsuka Pharmaceutical, indicating positive commercial progress.
- Narrowed Net Loss: The company recorded a net loss of $140 million for 2025, an improvement from $161 million in 2024, reflecting enhanced operational efficiency despite increased R&D spending.
- Clinical Trial Advancements: The 4FRONT-1 Phase 3 trial for 4D-150 in wet age-related macular degeneration (AMD) completed enrollment ahead of schedule, with topline data expected in the first half of 2027, marking rapid progress in critical therapeutic areas.
- Financial Stability: As of December 31, 2025, the company had $514 million in cash, cash equivalents, and marketable securities, bolstered by $118 million in financing, ensuring a cash runway extending into the second half of 2028.
See More
4D Molecular Therapeutics Reports FY 2025 Financial Highlights
- Earnings Performance: 4D Molecular Therapeutics reported a FY 2025 GAAP EPS of -$2.42, beating expectations by $0.98, indicating potential improvement in the company's financial performance.
- Collaboration Revenue Growth: The company achieved $85 million in collaboration and license revenue for 2025, a significant increase from $0 in 2024, marking a notable advancement in its commercialization efforts and laying a foundation for future growth.
- Cash Reserves: As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $514 million, ensuring ample funding for R&D and operations, thereby enhancing its competitive position in the market.
- Reduced Net Loss: The net loss for 2025 was $140 million, down from $161 million in 2024, reflecting improvements in cost control and operational efficiency, which may attract increased investor interest.
See More
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees
- Employee Incentive Program: On January 13, 2026, 4D Molecular Therapeutics' compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees, aimed at attracting talent and enhancing team stability.
- Equity Grant Context: The RSUs were awarded under the 2025 Employment Inducement Award Plan, approved by the board in February 2025, complying with Nasdaq Rule 5635(c)(4), reflecting the company's commitment to talent acquisition.
- Product Development Progress: The company's lead product, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods, showcasing transformative potential.
- Gene Therapy Innovation: The second candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, demonstrating the company's innovative capabilities and market potential in the therapeutic landscape.
See More
Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.
See More
4D Molecular Shares Decline Following Initial Trial Results for Cystic Fibrosis Treatment
Stock Performance: 4D Molecular Therapeutics (FDMT) shares fell approximately 15% following the announcement of updated data from an early-stage trial for its cystic fibrosis therapy, 4D-710.
Trial Findings: The Phase 1 AEROW clinical trial indicated no new safety events in higher-dose groups, leading the company to select a specific dose for the upcoming Phase 2 trial.
Trial Design: The AEROW trial evaluated different doses of 4D-710 in adults with cystic fibrosis lung disease who cannot tolerate standard CFTR modulator therapy.
Future Plans: 4D Molecular Therapeutics aims to complete enrollment for the Phase 2 Dose-Expansion cohort by the first half of 2026, with a program update anticipated in the latter half of the year.
See More
4D Molecular Therapeutics Reports Positive Interim Data for 4D-710 in Cystic Fibrosis Trial
- Positive Clinical Data: 4D-710 demonstrated good tolerability and achieved physiologically relevant CFTR expression levels in the AEROW trial, indicating potential clinical benefits across multiple lung function and symptom measures, suggesting its promise as a cystic fibrosis treatment.
- Patient Recruitment Progress: As of December 1, 2025, the AEROW trial has enrolled 16 cystic fibrosis patients, with no new safety events reported across different dose cohorts, underscoring the treatment's safety and efficacy.
- Successful Dose Selection: The 2.5E14 vg dose cohort showed clinically meaningful activity across all endpoints, supporting its selection for the next phase and further optimizing the treatment regimen.
- Future Milestones: The company anticipates completing enrollment of the AEROW Phase 2 Dose-Expansion cohort in H1 2026, further validating the efficacy of 4D-710, with plans to share additional updates in H2 2026.
See More
4D Molecular Therapeutics Reports 2025 Financial Highlights
- Revenue Growth: In 2025, 4D Molecular Therapeutics reported collaboration and license revenue of $85 million, primarily driven by an upfront payment from its strategic partnership with Otsuka Pharmaceutical, indicating positive commercial progress.
- Narrowed Net Loss: The company recorded a net loss of $140 million for 2025, an improvement from $161 million in 2024, reflecting enhanced operational efficiency despite increased R&D spending.
- Clinical Trial Advancements: The 4FRONT-1 Phase 3 trial for 4D-150 in wet age-related macular degeneration (AMD) completed enrollment ahead of schedule, with topline data expected in the first half of 2027, marking rapid progress in critical therapeutic areas.
- Financial Stability: As of December 31, 2025, the company had $514 million in cash, cash equivalents, and marketable securities, bolstered by $118 million in financing, ensuring a cash runway extending into the second half of 2028.
See More
4D Molecular Therapeutics Reports FY 2025 Financial Highlights
- Earnings Performance: 4D Molecular Therapeutics reported a FY 2025 GAAP EPS of -$2.42, beating expectations by $0.98, indicating potential improvement in the company's financial performance.
- Collaboration Revenue Growth: The company achieved $85 million in collaboration and license revenue for 2025, a significant increase from $0 in 2024, marking a notable advancement in its commercialization efforts and laying a foundation for future growth.
- Cash Reserves: As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $514 million, ensuring ample funding for R&D and operations, thereby enhancing its competitive position in the market.
- Reduced Net Loss: The net loss for 2025 was $140 million, down from $161 million in 2024, reflecting improvements in cost control and operational efficiency, which may attract increased investor interest.
See More
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees
- Employee Incentive Program: On January 13, 2026, 4D Molecular Therapeutics' compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees, aimed at attracting talent and enhancing team stability.
- Equity Grant Context: The RSUs were awarded under the 2025 Employment Inducement Award Plan, approved by the board in February 2025, complying with Nasdaq Rule 5635(c)(4), reflecting the company's commitment to talent acquisition.
- Product Development Progress: The company's lead product, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods, showcasing transformative potential.
- Gene Therapy Innovation: The second candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, demonstrating the company's innovative capabilities and market potential in the therapeutic landscape.
See More
Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.
See More
4D Molecular Shares Decline Following Initial Trial Results for Cystic Fibrosis Treatment
Stock Performance: 4D Molecular Therapeutics (FDMT) shares fell approximately 15% following the announcement of updated data from an early-stage trial for its cystic fibrosis therapy, 4D-710.
Trial Findings: The Phase 1 AEROW clinical trial indicated no new safety events in higher-dose groups, leading the company to select a specific dose for the upcoming Phase 2 trial.
Trial Design: The AEROW trial evaluated different doses of 4D-710 in adults with cystic fibrosis lung disease who cannot tolerate standard CFTR modulator therapy.
Future Plans: 4D Molecular Therapeutics aims to complete enrollment for the Phase 2 Dose-Expansion cohort by the first half of 2026, with a program update anticipated in the latter half of the year.
See More
4D Molecular Therapeutics Reports Positive Interim Data for 4D-710 in Cystic Fibrosis Trial
- Positive Clinical Data: 4D-710 demonstrated good tolerability and achieved physiologically relevant CFTR expression levels in the AEROW trial, indicating potential clinical benefits across multiple lung function and symptom measures, suggesting its promise as a cystic fibrosis treatment.
- Patient Recruitment Progress: As of December 1, 2025, the AEROW trial has enrolled 16 cystic fibrosis patients, with no new safety events reported across different dose cohorts, underscoring the treatment's safety and efficacy.
- Successful Dose Selection: The 2.5E14 vg dose cohort showed clinically meaningful activity across all endpoints, supporting its selection for the next phase and further optimizing the treatment regimen.
- Future Milestones: The company anticipates completing enrollment of the AEROW Phase 2 Dose-Expansion cohort in H1 2026, further validating the efficacy of 4D-710, with plans to share additional updates in H2 2026.
See More
